On July, 5 VistaGen Therapeutics, Inc. (VTGN) Analysts See $-0.28 EPS

June 27, 2018 - By Daniel Cummings

VistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s earnings release is expected by WallStreet on July, 5, Zacks reports. Analysts predict 12.50 % diference or $-0.28 from the $-0.32 EPS from 2017. 16.67 % negative EPS growth is what Wall Street’s predicts after $-0.24 reported EPS previous quarter. VTGN hit $1.35 during the last trading session after $0.01 change.Currently VistaGen Therapeutics, Inc. is downtrending after 19.67% change in last June 27, 2017. VTGN has 135,334 shares volume. The stock underperformed the S&P500 by 32.24%.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system disorders.The firm is worth $30.80 million. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.Last it reported negative earnings. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells.

Another two news for VistaGen Therapeutics, Inc. (NASDAQ:VTGN) were recently posted by: Nasdaq.com on June 13, 2018 with title “VistaGen Therapeutics Issued Two Key US Patents for Treatment of Depression with AV-101”. The other Nasdaq.com‘s article was titled “VistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights” and posted on June 26, 2018.

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.